MARKET

BAX

BAX

Baxter Intl Inc
NYSE

Real-time Quotes | Nasdaq Last Sale

65.49
+1.26
+1.96%
After Hours: 65.70 +0.21 +0.32% 16:50 07/01 EDT
OPEN
64.18
PREV CLOSE
64.23
HIGH
65.62
LOW
63.71
VOLUME
2.52M
TURNOVER
0
52 WEEK HIGH
89.70
52 WEEK LOW
63.25
MARKET CAP
32.98B
P/E (TTM)
31.40
1D
5D
1M
3M
1Y
5Y
UPDATE 2-In historic shift, Toshiba board gains two directors from activist hedge funds
UPDATE 2-In historic shift, Toshiba board gains two directors from activist hedge funds
Reuters · 4d ago
BAXTER DETAILS PROGRESS TOWARD ENVIRONMENTAL, SOCIAL AND GOVERNANCE (ESG) PRIORITIES IN ANNUAL CORPORATE RESPONSIBILITY REPORT
Baxter International Inc. (NYSE: BAX), a global medtech leader, today released its 2021 Corporate Responsibility Report, demonstrating how the company is progressing toward its 2030 Corporate Responsibility Commitment and Goals. The report highlights the c...
CNW Group · 5d ago
Baxter Details Progress Toward Environmental, Social and Governance (ESG) Priorities in Annual Corporate Responsibility Report
DEERFIELD, Ill., June 27, 2022--Baxter International Inc. (NYSE:BAX), a global medtech leader, today released its 2021 Corporate Responsibility Report, demonstrating how the company is progressing toward its 2030 Corporate Responsibility Commitment and Goa...
Business Wire · 5d ago
What 9 Analyst Ratings Have To Say About Baxter Intl
Over the past 3 months, 9 analysts have published their opinion on Baxter Intl (NYSE:BAX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the ...
Benzinga · 06/24 15:26
Baxter downgraded at Wells Fargo citing headwinds to near-term outlook
Baxter International (NYSE:BAX) is trading lower in the pre-market Friday on below-average volume after Wells Fargo downgraded the health equipment maker to Equal Weight from Overweight, noting pressure on the
Seekingalpha · 06/24 12:19
U.S. FDA labels Baxter's respiratory device recall as most serious
reuters.com · 06/23 13:42
Food and Drug Administration Says Baxter Recalls Volara System For Risk Of Respiratory Distress
MT Newswires · 06/23 10:10
--Street Color: FDA Says Baxter International Recalls Volara System For Risk of Respiratory Distress
MT Newswires · 06/23 09:22
More
No Data
Learn about the latest financial forecast of BAX. Analyze the recent business situations of Baxter Intl Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 15 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

20.00%Strong Buy
53.33%Buy
20.00%Hold
6.67%Under-perform
0.00%Sell
Analyst Price Target
The average BAX stock price target is 86.85 with a high estimate of 100.00 and a low estimate of 70.00.
High100.00
Average86.85
Low70.00
Current 65.49
EPS
Actual
Estimate
0.260.520.781.04
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 1.58K
Institutional Holdings: 467.82M
% Owned: 92.91%
Shares Outstanding: 503.53M
TypeInstitutionsShares
Increased
353
28.29M
New
102
4.42M
Decreased
411
27.43M
Sold Out
99
2.20M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
+2.13%
Healthcare Equipment & Supplies
+1.92%
Key Executives
Chairman/President/Chief Executive Officer/Director
Jose Almeida
Chief Financial Officer/Executive Vice President
James Saccaro
Chief Operating Officer/Executive Vice President
Giuseppe Accogli
Senior Vice President/General Counsel
Sean Martin
Senior Vice President/Director of Human Resources
Jeanne Mason
Senior Vice President
James Borzi
Senior Vice President
Cristiano Franzi
Senior Vice President
Andrew Frye
Senior Vice President
Jacqueline Kunzler
Lead Director/Independent Director
Albert Stroucken
Independent Director
Thomas Chen
Independent Director
Peter Hellman
Independent Director
Michael Mahoney
Independent Director
Amy Mcbride-Wendell
Independent Director
Patricia Morrison
Independent Director
Stephen Oesterle
Independent Director
Nancy Schlichting
Independent Director
D. Brent Shafer
Independent Director
Cathy Smith
Independent Director
David Wilkes
Independent Director
Peter Wilver
No Data
No Data
About BAX
Baxter International Inc., through its subsidiaries, provides a portfolio of essential healthcare products. The Company’s products include renal care, medication delivery, pharmaceuticals, clinical nutrition, advanced surgery and acute therapies. Its renal care offering includes peritoneal dialysis (PD), hemodialysis (HD) and additional dialysis therapies and services. Its medication delivery offerings include intravenous (IV) therapies, infusion pumps, administration sets and drug reconstitution devices. Its pharmaceuticals offerings include premixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services. Its clinical nutrition offerings include parenteral nutrition (PN) therapies and related products. Its advanced surgery offerings include biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention. It also offers polysaccharide hemostatic system (PerClot) products.

Webull offers kinds of Baxter International Inc stock information, including NYSE:BAX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BAX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BAX stock methods without spending real money on the virtual paper trading platform.